As of September 09, 2026, Polaryx Therapeutics's top three insider holders are Alex Keun Mo Yang (Chief Executive Officer, 24.23Mn shares), G. Michael Landis (Chief Financial Officer, 228.22K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Alex Keun Mo Yang | Chief Executive Officer | 0 | 24,233,249 | 24,233,249 | 99.1% | 28 May, 2026 |
| 2 | G. Michael Landis | Chief Financial Officer | 228,225 | 0 | 228,225 | 0.9% | 20 Feb, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 27 May, 2026 | Alex Keun Mo Yang | Chief Executive Officer | Acquired P | 88,453 | $4.07 | $360.00K | 24,233,249 | Indirect |
| 18 Feb, 2026 | G. Michael Landis | Chief Financial Officer | Acquired P | 2,867 | $2.79 | $7.99K | 228,225 | Direct |